Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nexiguran ziclumeran · 1 trial · 20 indications
| Arm | Type | Description |
|---|---|---|
| nexiguran ziclumeran | EXPERIMENTAL | nexiguran ziclumeran 55 mg by single IV infusion |
| Normal Saline | PLACEBO_COMPARATOR | Placebo; Normal saline (0.9% NaCl) by single IV infusion |
| Name | Type | Description |
|---|---|---|
| nexiguran ziclumeran | BIOLOGICAL | nexiguran ziclumeran 55 mg by single IV infusion |
| Normal Saline as Placebo | DRUG | Normal saline (0.9% NaCl) by single IV infusion |
Inclusion Criteria: * Diagnosis of ATTRv-PN * Karnofsky Performance Status (KPS) ≥ 60 Exclusion Criteria: * Other causes of amyloidosis (amyloidosis caused by non-TTR protein) * Other known causes of sensorimotor or autonomic neuropathy * Diabetes mellitus * New York Heart Association Class III o...
Nexiguran ziclumeran is an investigational therapy being developed for the treatment of neuromuscular disease, specifically hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). It is currently in Phase 3 clinical development and has received FDA designations including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designation.
Nexiguran ziclumeran is a monoclonal antibody being developed by Intellia Therapeutics. While the specific molecular target is not disclosed in the available information, the drug is being studied in a Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy, a condition caused by the accumulation of abnormal transthyretin protein.
Nexiguran ziclumeran is being developed by Intellia Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NTLA. The company is conducting a Phase 3 clinical trial of the drug for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.
Nexiguran ziclumeran is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the FDA for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.
Nexiguran ziclumeran is being evaluated in a Phase 3 clinical trial registered as NCT06672237, titled 'A Phase 3 Study of NTLA-2001 in ATTRv-PN'. This randomized, double-blind, placebo-controlled study is recruiting 60 participants aged 18 years and older across Argentina, Brazil, Mexico, Singapore, Taiwan, and Thailand.
Yes, nexiguran ziclumeran is also known as NTLA-2001. The Phase 3 clinical trial NCT06672237, which is evaluating the drug for hereditary transthyretin amyloidosis with polyneuropathy, is titled 'A Phase 3 Study of NTLA-2001 in ATTRv-PN'.